Healthcare Professionals Site

Apply for the Genentech Patient Foundation.

Genentech Patient Foundation

To get started:

  • Complete the Patient Consent Form, which is available in English and Spanish, below:
  • Once you have completed the Patient Consent Form, please inform your doctor's office and let them know that you are applying for assistance from the Genentech Patient Foundation for Pulmozyme. Your doctor will have to complete another form called the Prescriber Foundation Form. Both forms are required. No action can be taken until a completed Patient Consent Form and Prescriber Foundation Form have been received.

What to expect next:

  • The request will be processed within 5 business days upon receipt of both required forms
  • You and your provider will be contacted to discuss the application outcome and any next steps

Genentech reserves the right to modify or discontinue the program at any time and to verify the accuracy of information submitted.

 

Contact Us

Questions? Contact a Foundation Specialist

Call 888-941-3331 (Mon.–Fri., 6AM–5PM PST)

Back to Pulmozyme Financial Support Tool

Indication & Usage

Pulmozyme (dornase alfa) is indicated for daily administration along with standard therapies for the management of cystic fibrosis (CF) patients to improve pulmonary function.

In CF patients with an FVC ≥ 40% of predicted, daily administration of Pulmozyme has also been shown to reduce the risk of respiratory tract infections requiring injectable antibiotics.

Important Safety Information

Pulmozyme should not be used in patients who are allergic to any of its ingredients.

Patients may experience the following when using Pulmozyme: change in or loss of their voice, discomfort in the throat, rash, chest pain, red watery eyes, runny nose, lowering of lung function, fever, indigestion, and shortness of breath. There have been no reports of severe allergic reactions caused by the administration of Pulmozyme. Mild to moderate hives and mild skin rash have been observed and have been short-lived.

Pediatric Use

The safety and effectiveness of Pulmozyme have been established in patients 5 years of age and older. While clinical trial data are limited in patients younger than 5 years of age, the use of Pulmozyme should be considered for pediatric CF patients who may experience potential benefit in lung function or who may be at risk of respiratory tract infection.

The safety of Pulmozyme given by daily inhalation for 2 weeks has been studied using 98 CF patients with 65 of them aged 3 months to <5 years (younger group) and 33 aged 5 years to <10 years (older group). The PARI BABY™ reusable nebulizer (which uses a face mask instead of a mouthpiece) was used in patients who were unable to show that they could breathe in or out using their mouth throughout the entire treatment period. Overall, the kind of side effects observed in children was similar to those seen in larger trials in older patients.

You are encouraged to report side effects to Genentech and the FDA. You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.

Please see full Pulmozyme Prescribing Information for additional Important Safety Information. If you have questions, please discuss them with your CF Care Team.

Link to Healthcare Professionals Site

The information contained in this section of the site is intended for U.S. healthcare professionals only. Click "OK" if you are a healthcare professional.

Link to Third-Party Site

The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.